UNSPSC 51392406: Levonordefrin

This classification denotes an adrenergic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V008L6478D. European Medicines Agency schedules Corbadrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06805MIG. Corbadrine generally arises in the molecular formula C9H13NO3.

The term CORBADRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, no. 5 1981, list 21.) CORBADRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, LEVONORDEFRIN remains the US FDA Preferred Term for this commodity. Levonordefrin bears US NLM identifiers UMLS ID C0520472 and NCI Concept Code C47584. SMILES: OC(C(N)C)C1CC(O)C(O)CC1.

UNSPSC 51392406 Levonordefrin, a Commodity code, appears in state and local procurement activity focused on emergency response pharmaceuticals and drug-related public health interventions rather than the specific vasoconstrictor compound the code nominally names. Recent solicitations tag the code to procurements for naloxone (opioid-overdose reversal medication) and drug deactivation systems, reflecting how state and local buyers use UNSPSC taxonomy to capture pharmaceutical supply chains serving community health, emergency management, and substance-abuse response programs. The mix of issuing bodies includes county health departments and state human services agencies; Seminole County, Florida and the Texas Health and Human Services Commission appear in the recent record.

Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023 and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs that would establish relationships between the state pharmacy benefit program and pharmaceutical manufacturers outside traditional pharmacy benefit manager and wholesaler channels. Geographic activity is concentrated in Florida and Texas based on the recent record, with no broader state pattern evident from the available solicitations.